Drug intelligence / Profile preview

thymosin beta-4

Development stage
Phase 2
Lead developer
RegeneRx Biopharmaceuticals
Modality
Peptides, Recombinant Proteins and Enzymes
Administration
Intravenous, Subcutaneous, Intramuscular, Topical, Ophthalmic, Inhalation, Intrathecal
01

Overview

Thymosin beta-4 is a naturally occurring peptide composed of 43 amino acids and is found in many tissues throughout the body. It was initially identified as a thymic hormone but is now recognized primarily for its role as an actin-sequestering protein. Thymosin beta-4 regulates the availability of G-actin monomers in cells and plays a critical role in cell migration, tissue repair, regeneration, angiogenesis (formation of new blood vessels), anti-inflammatory responses, and reduction of fibrosis. Its mechanism involves binding to actin to promote cell movement and mobilization/differentiation of stem/progenitor cells for tissue regeneration. Thymosin beta-4 has been investigated for use in healing sports injuries; soft tissue repair; treatment of pressure ulcers; immune support; cardioprotection after myocardial infarction; neuroprotection (including multiple sclerosis and traumatic brain injury); ocular disorders such as dry eye syndrome and corneal wound healing; diabetic retinopathy; sepsis; chemical burns; non-alcoholic fatty liver disease (NAFLD); lung inflammation/fibrosis; hair growth stimulation among others[1][2][3][5][6].

Brand names
TB-500TB500TB 500
Other names
Tβ4thymosin β4thymosin beta 4
02

Targets

RELA (Nuclear Factor Kappa B Subunit p65)LIMS1 (LIM and senescent cell antigen-like-containing domain protein 1)ILK (Integrin-linked kinase)

Beyond the preview

Go deeper on thymosin beta-4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on thymosin beta-4.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call